

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



丽珠医药  
LIVZON

麗珠醫藥集團股份有限公司

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **PROPOSED CHANGE OF AUDITOR FOR THE YEAR 2019**

This announcement is made by the board of directors (the “**Board**”) of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

In consideration of the development needs of the Company, the Board proposes Ruihua Certified Public Accountants (LLP) (瑞華會計師事務所(特殊普通合夥)) (“**Ruihua**”) to be terminated as the auditor of the Company for the year 2019 (the “**Proposed Termination**”).

The Board also proposes Grant Thornton (Special General Partnership) to be appointed as the auditor of the Company for the year 2019 (the “**Proposed Appointment**”), and its remuneration to be fixed at RMB1.64 million (tax inclusive) and RMB0.36 million (tax inclusive) for the audit of the financial statements of the Company for the year 2019 and the internal control of the Company respectively.

Ruihua has confirmed in writing that there are no matters in relation to the Proposed Termination that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”). The Board and the audit committee of the Company have also confirmed that there are no disagreements or outstanding matters between the Company and Ruihua, and the Board is not aware of any other matters in relation to the change of auditor that need to be brought to the attention of the Shareholders.

The Proposed Termination and the Proposed Appointment are subject to the approval by the Shareholders at an extraordinary general meeting to be held. A circular containing the details of the change of auditor will be despatched to the Shareholders in accordance with the Listing Rules as soon as possible.

The Board would like to express its sincere gratitude to Ruihua for the professional and quality services rendered to the Company in the past years.

By order of the Board  
麗珠醫藥集團股份有限公司  
**Livzon Pharmaceutical Group Inc.\***  
**Yang Liang**  
*Company Secretary*

Zhuhai, China  
22 October 2019

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.*

*\* For identification purpose only*